Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study

Florence Demenais, H Mohamdi, Valerie Chaudru, Alisa M. Goldstein, Julia A. Newton-Bishop, D T Bishop, Peter A. Kanetsky, N. K. Hayward, Elizabeth M. Gillanders, David E. Elder, Marie Francoise Avril, Esther Azizi, Patricia Van Belle, Wilma Bergman, Giovanna Bianchi-Scarrà, Brigitte Bressac-De Paillerets, Donato Calista, Cristina Carrera, Johan Hansson, Mark HarlandDavid Hogg, Veronica Höiom, E. A. Holland, Christian Ingvar, Maria Teresa Landi, J M Lang, R M Mackie, G. J. Mann, M E Ming, C J Njauw, Håkan Olsson, J Palmer, Lorenza Pastorino, Susana Puig, Juliette A. Randerson-Moor, M Stark, Hensin Tsao, M A Tucker, D. P. Van Velden, X R Yang, Nelleke A. Gruis, Melanoma Genetics Consortium

Research output: Contribution to journalArticlepeer-review

103 Citations (Scopus)


BACKGROUND: Carrying the cyclin-dependent kinase inhibitor 2A (CDKN2A) germline mutations is associated with a high risk for melanoma. Penetrance of CDKN2A mutations is modified by pigmentation characteristics, nevus phenotypes, and some variants of the melanocortin-1 receptor gene (MC1R), which is known to have a role in the pigmentation process. However, investigation of the associations of both MC1R variants and host phenotypes with melanoma risk has been limited.

METHODS: We included 815 CDKN2A mutation carriers (473 affected, and 342 unaffected, with melanoma) from 186 families from 15 centers in Europe, North America, and Australia who participated in the Melanoma Genetics Consortium. In this family-based study, we assessed the associations of the four most frequent MC1R variants (V60L, V92M, R151C, and R160W) and the number of variants (1, ≥2 variants), alone or jointly with the host phenotypes (hair color, propensity to sunburn, and number of nevi), with melanoma risk in CDKN2A mutation carriers. These associations were estimated and tested using generalized estimating equations. All statistical tests were two-sided.

RESULTS: Carrying any one of the four most frequent MC1R variants (V60L, V92M, R151C, R160W) in CDKN2A mutation carriers was associated with a statistically significantly increased risk for melanoma across all continents (1.24 × 10(-6) ≤ P ≤ .0007). A consistent pattern of increase in melanoma risk was also associated with increase in number of MC1R variants. The risk of melanoma associated with at least two MC1R variants was 2.6-fold higher than the risk associated with only one variant (odds ratio = 5.83 [95% confidence interval = 3.60 to 9.46] vs 2.25 [95% confidence interval = 1.44 to 3.52]; P(trend) = 1.86 × 10(-8)). The joint analysis of MC1R variants and host phenotypes showed statistically significant associations of melanoma risk, together with MC1R variants (.0001 ≤ P ≤ .04), hair color (.006 ≤ P ≤ .06), and number of nevi (6.9 × 10(-6) ≤ P ≤ .02).

CONCLUSION: Results show that MC1R variants, hair color, and number of nevi were jointly associated with melanoma risk in CDKN2A mutation carriers. This joint association may have important consequences for risk assessments in familial settings.

Original languageEnglish
Pages (from-to)1568-83
Number of pages16
JournalJournal of the National Cancer Institute
Issue number20
Publication statusPublished - 20 Oct 2010
Externally publishedYes


  • Adult
  • Australia
  • Cyclin-Dependent Kinase Inhibitor p16
  • Europe
  • European Continental Ancestry Group
  • Female
  • Genes, p16
  • Hair Color
  • Heterozygote
  • Humans
  • Male
  • Melanoma
  • Mutation
  • Nevus
  • North America
  • Phenotype
  • Receptor, Melanocortin, Type 1
  • Risk Assessment
  • Risk Factors
  • Skin Neoplasms
  • Skin Pigmentation
  • Sunburn
  • Journal Article
  • Multicenter Study
  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural
  • Research Support, Non-U.S. Gov't


Dive into the research topics of 'Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study'. Together they form a unique fingerprint.

Cite this